登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式(希尔记法):
C28H25FN6O3
化学文摘社编号:
分子量:
512.53
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
产品名称
LY2090314, ≥98% (HPLC)
InChI
1S/C28H25FN6O3/c29-18-12-17-15-34(28(38)32-7-3-1-4-8-32)11-10-33-16-20(19(13-18)25(17)33)23-24(27(37)31-26(23)36)21-14-30-22-6-2-5-9-35(21)22/h2,5-6,9,12-14,16H,1,3-4,7-8,10-11,15H2,(H,31,36,37)
SMILES string
O=C(N1CCCCC1)N(C2)CCN3C4=C2C=C(F)C=C4C(C5=C(C6=CN=C7N6C=CC=C7)C(NC5=O)=O)=C3
InChI key
HRJWTAWVFDCTGO-UHFFFAOYSA-N
assay
≥98% (HPLC)
form
powder
color
yellow to orange
solubility
DMSO: 10 mg/mL, clear
storage temp.
−20°C
Quality Level
Gene Information
human ... GSK3A(2931), GSK3B(2932)
Biochem/physiol Actions
LY2090314 can decrease the development of human MYCN amplified and non-amplified neuroblastoma (NB) cell lines in vitro. It has the ability to prevent the multiplication, colony formation and cell confluency of neuroblastoma.
LY2090314 is a potent and selective ATP-competitive inhibitor of Glycogen synthase kinase-3 (GSK-3) currently in clinical trials for cancer therapy. LY2090314 has IC50 values of 1.5 nM and 0.9 nM for GSK-3α and GSK-3β, respectively.
LY2090314 is a potent and selective ATP-competitive inhibitor of Glycogen synthase kinase-3 (GSK-3).
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Antiproliferative and apoptotic effect of LY2090314, a GSK-3 inhibitor, in neuroblastoma in vitro
Kunnimalaiyaan S, et al.
BMC Cancer, 18(1), 560-560 (2018)
Mengfei Yu et al.
Cell, 184(1), 243-256 (2021-01-09)
Craniosynostosis results from premature fusion of the cranial suture(s), which contain mesenchymal stem cells (MSCs) that are crucial for calvarial expansion in coordination with brain growth. Infants with craniosynostosis have skull dysmorphology, increased intracranial pressure, and complications such as neurocognitive
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持